|
|
|
|
| LEADER |
02595nam a2200289 u 4500 |
| 001 |
EB001840266 |
| 003 |
EBX01000000000000001004255 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Buprenorphine/naloxone versus methadone for the treatment of opioid dependence
|h Elektronische Ressource
|b a review of comparative clinical effectiveness, cost-effectiveness and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 02 September 2016
|
| 300 |
|
|
|a 1 PDF file (50 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Buprenorphine, Naloxone Drug Combination
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Buprenorphine, Naloxone Drug Combination / therapeutic use
|
| 653 |
|
|
|a Opioid-Related Disorders / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: peer-Reviewed summary with critical appraisal
|
| 500 |
|
|
|a "CADTH Rapid Response Service."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK385163
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a In 2013, Suboxone (buprenorphine/naloxone) became available as a generic and its direct cost, and cost differential with methadone, decreased. Buprenorphine/naloxone has several advantages compared with methadone. Methadone is a full agonist; there is no ceiling to respiratory depression or sedation effects and an overdose can be fatal. Buprenorphine also has a long half-life but because it is a partial agonist, it has a ceiling effect (effect plateaus at higher doses) and thus the risk of overdose is decreased. Other advantages of buprenorphine/naloxone include its long duration of action which allows for every second day dosing if needed; its administration as a sublingual tablet; its lack of requirements of an exemption to be prescribed; and its formulation with less potential for abuse. Given the foregoing, an assessment is required to assist decision-makers and prescribers in selecting between the two treatments. Hence, the purpose of this review is to provide evidence on the comparative clinical effectiveness and cost-effectiveness of buprenorphine/naloxone compared with methadone, for the treatment of patients with opioid use disorder. Clinical practice guidelines will also be examined
|